Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

Objective: To test agent and cell-type specificity in insulin resistance induced by prolonged exposure to HIV protease inhibitors (HPI), and to assess its relation to the direct, short-term inhibition of insulin-stimulated glucose uptake. Methods: Following prolonged (18 h) and short (5–10 min) exposure to HPI, insulin-stimulated glucose transport, protein kinase B (PKB) phosphorylation, and GLUT4 translocation were evaluated in 3T3-L1 adipocytes, fibroblasts, L6 myotubes, and L6 cells overexpressing a myc tag on the first exofacial loop of GLUT4 or GLUT1. Results: Prolonged exposure of 3T3-L1 adipocytes to nelfinavir, but not to indinavir or saquinavir, resulted in increased basal lipolysis but decreased insulin-stimulated glucose transport and PKB phosphorylation. In addition, impaired insulin-stimulated glucose uptake and PKB phosphorylation were also observed in the skeletal muscle cell line L6, and in 3T3-L1 fibroblasts. Interestingly, this coincided with increased basal glucose uptake as well as with elevated total-membrane glucose transporter GLUT1 protein content. In contrast to these unique effects of nelfinavir, the mere presence of any of the agents in the 5 min transport assay inhibited insulin-stimulated glucose-uptake activity. This appeared to be caused by direct and specific interaction of the drugs with GLUT4 fully assembled at the plasma membrane, since insulin-stimulated cell-surface exposure of an exofacial myc epitope on GLUT4 was normal. Conclusions: Independent mechanisms for HPI-induced insulin resistance exist: prolonged exposure to nelfinavir interferes with insulin signaling and alters cellular metabolism of adipocytes and muscle cells, whereas a direct inhibitory effect on insulin-stimulated glucose uptake may occurs through specific interaction of HPI with GLUT4.

[1]  S. Frost,et al.  Differential regulation of GRP78 and GLUT1 expression in 3T3-L1 adipocytes , 1996, Molecular and Cellular Biochemistry.

[2]  P. Hruz,et al.  Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations , 2002, AIDS.

[3]  P. Hruz,et al.  Indinavir induces acute and reversible peripheral insulin resistance in rats. , 2002, Diabetes.

[4]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[5]  R. Roche,et al.  Effects of antiretroviral drug combinations on the differentiation of adipocytes , 2002, AIDS.

[6]  P. Kern,et al.  The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. , 2002, The Journal of endocrinology.

[7]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[8]  H. Jamil,et al.  HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia , 2001, Nature Medicine.

[9]  D. Mondal,et al.  Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. , 2001, AIDS research and human retroviruses.

[10]  P. Reiss,et al.  Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways , 2001, AIDS.

[11]  D. Kotler,et al.  Clinical perspectives on HIV-associated lipodystrophy syndrome: an update , 2001, AIDS.

[12]  V. Randhawa,et al.  Hyperosmolarity Reduces GLUT4 Endocytosis and Increases Its Exocytosis from a VAMP2-independent Pool in L6 Muscle Cells* , 2001, The Journal of Biological Chemistry.

[13]  I. Harman-boehm,et al.  The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. , 2001, Diabetes.

[14]  K. Yarasheski,et al.  The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. , 2001, Diabetes.

[15]  C. Vigouroux,et al.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. , 2001, Diabetes.

[16]  M. Schambelan,et al.  Metabolic effects of indinavir in healthy HIV-seronegative men , 2001, AIDS.

[17]  H. Koh,et al.  Cyclic AMP Inhibits Akt Activity by Blocking the Membrane Localization of PDK1* , 2001, The Journal of Biological Chemistry.

[18]  P. Hruz,et al.  Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism. , 2001, American journal of physiology. Endocrinology and metabolism.

[19]  R. Hogg,et al.  Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database , 2001, AIDS.

[20]  J. McGarry.  Dysregulation of Fatty Acid Metabolism in the Etiology of Type 2 Diabetes , 2001 .

[21]  C. Flexner,et al.  Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors* , 2000, The Journal of Biological Chemistry.

[22]  J. Klein,et al.  The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells , 2000, Diabetologia.

[23]  E. Furfine,et al.  HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. , 2000, Antiviral research.

[24]  P. Hruz,et al.  The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy* , 2000, The Journal of Biological Chemistry.

[25]  J. Mei,et al.  Down-regulation of cyclic-nucleotide phosphodiesterase 3B in 3T3-L1 adipocytes induced by tumour necrosis factor alpha and cAMP. , 2000, The Biochemical journal.

[26]  M. Schambelan,et al.  Hyperlipidemia and Insulin Resistance Are Induced by Protease Inhibitors Independent of Changes in Body Composition in Patients With HIV Infection , 2000, Journal of acquired immune deficiency syndromes.

[27]  A. Klibanski,et al.  Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. , 2000, The Journal of clinical endocrinology and metabolism.

[28]  G. Mathé.  Human obesity and thinness, hyperlipidemia, hyperglycemia, and insulin resistance associated with HIV1 protease inhibitors. Prevention by alternating several antiproteases in short sequences. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[29]  S. Piscitelli,et al.  Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  J. Berger,et al.  Inhibition of adipocyte differentiation by HIV protease inhibitors. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  W. Rozenbaum,et al.  Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). , 1999, Diabetes & metabolism.

[32]  C. Wanke.  Epidemiological and clinical aspects of the metabolic complications of HIV infection the fat redistribution syndrome. , 1999, AIDS.

[33]  H. Schmidt,et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.

[34]  K. Yarasheski,et al.  Insulin resistance in HIV protease inhibitor-associated diabetes. , 1999, Journal of acquired immune deficiency syndromes.

[35]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[36]  C. Tsigos,et al.  Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. , 1999, The Journal of clinical endocrinology and metabolism.

[37]  S. Heymsfield,et al.  Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. , 1999, The American journal of clinical nutrition.

[38]  A. Rudich,et al.  Oxidative Stress Disrupts Insulin-induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes , 1999, The Journal of Biological Chemistry.

[39]  I. Weller,et al.  Lipodystrophy in patients naive to HIV protease inhibitors. , 1999, AIDS.

[40]  J. Wang,et al.  Studies of body composition and fat distribution in HIV-infected and control subjects. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[41]  D L Rothman,et al.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. , 1999, The Journal of clinical investigation.

[42]  Y. Kao,et al.  Synergistic effect of arachidonic acid and cyclic AMP on glucose transport in 3T3-L1 adipocytes. , 1999, Cellular signalling.

[43]  F. Goebel,et al.  Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV‐1‐infected patients , 1998, AIDS.

[44]  A. Rudich,et al.  Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. , 1998, Diabetes.

[45]  J. Touraine,et al.  “Buffalo hump” in HIV-1 infection , 1998, The Lancet.

[46]  D. Cooper,et al.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance , 1998, The Lancet.

[47]  A. Klip,et al.  GLUT4 translocation by insulin in intact muscle cells: detection by a fast and quantitative assay , 1998, FEBS letters.

[48]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[49]  Morris Schambelan,et al.  “Buffalo hump” in men with HIV-1 infection , 1998, The Lancet.

[50]  Calvin Cohen,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease , 1998, The Lancet.

[51]  C Maurath,et al.  Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. , 1998, Lancet.

[52]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[53]  R. Hardy,et al.  Saturated fatty Acid–Induced Insulin Resistance in Rat Adipocytes , 1994, Diabetes.

[54]  Y. Mitsumoto,et al.  Development regulation of the subcellular distribution and glycosylation of GLUT1 and GLUT4 glucose transporters during myogenesis of L6 muscle cells. , 1992, The Journal of biological chemistry.

[55]  K. Kaestner,et al.  Transcriptional repression of the mouse insulin-responsive glucose transporter (GLUT4) gene by cAMP. , 1991, Proceedings of the National Academy of Sciences of the United States of America.